Early phosphoproteomic changes in the retina following optic nerve crush

Yang Liu1, Huahong Zhong2, Emily L Bussan3

  • 1Department of Pharmacology & Neuroscience, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.

Experimental Neurology
|September 24, 2020
PubMed

Insights

Optic nerve injury triggers significant retinal protein phosphorylation changes, impacting astrocyte function and offering new therapeutic targets for blindness and neurodegeneration.

Area of Science:

  • Neuroscience
  • Proteomics
  • Ophthalmology

Background:

  • Retinal ganglion cell (RGC) death leads to irreversible blindness.
  • RGC degeneration is implicated in glaucoma and optic nerve (ON) injuries.
  • Understanding RGC degeneration mechanisms is crucial for developing treatments.

Purpose of the Study:

  • To investigate the phosphoproteomic changes in the retina following optic nerve injury.
  • To identify key proteins and pathways involved in RGC degeneration.
  • To explore the role of phosphoprotein enriched in astrocytes 15 (PEA15) in astrocyte function.

Main Methods:

  • Optic nerve crush (ONC) model in adult mice.
  • Phosphoproteomic analysis using 2D-PAGE, phosphoprotein staining, and MALDI-TOF/TOF MS.
  • Western blotting and immunofluorescence staining for PEA15 validation.
  • Functional assays in cultured astrocytes with PEA15 knockdown.

Main Results:

  • ONC induced significant phosphorylation changes in numerous retinal proteins.
  • 29 significantly phosphorylated proteins were identified, associated with diverse biological functions.
  • PEA15 knockdown altered astrocyte phagocytosis, migration, and ATP levels.
  • PEA15 was identified as a key player in the retinal response to injury.

Conclusions:

  • Optic nerve injury triggers complex phosphoproteomic alterations in the retina.
  • PEA15 plays a critical role in astrocyte function, influencing their response to injury.
  • These findings provide novel insights into RGC degeneration and potential therapeutic targets for neurodegenerative diseases affecting the central nervous system (CNS).